Business Context and Reporting Period
This Form 8-K Current Report from Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) covers the Annual Meeting of Stockholders held on November 1, 2021. The filing details the voting results for three proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance data.
Material Changes and Voting Results
Stockholders voted on three key proposals at the November 1, 2021 meeting:
- Proposal 1: Election of Directors. Seven individuals were elected to the Board of Directors to serve until the 2022 annual meeting. All nominees received significant majority support, with "For" votes ranging from approximately 64.8 million to 66.2 million shares. Notable non-votes (broker non-votes) totaled 53,753,479 shares for each director.
- Proposal 2: Ratification of Auditors. Stockholders approved the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021. The vote was 119,254,551 "For" versus 397,251 "Against" and 724,280 "Abstain."
- Proposal 3: Executive Compensation. Stockholders approved, on an advisory basis, the compensation of named executive officers. The vote was 62,726,470 "For" versus 3,055,624 "Against" and 840,509 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the final tabulation of shareholder votes.
Investor Verification Checklist
- Verify the composition of the newly elected Board of Directors and their tenure terms.
- Confirm the appointment of EisnerAmper LLP as the independent auditor for the 2021 fiscal year.
- Review the definitive proxy statement filed on September 17, 2021, for detailed descriptions of the executive compensation package approved by shareholders.
- Note the significant number of broker non-votes (53,753,479) recorded for the director elections and executive compensation proposal.